Skip to main content

Table 2 Univariate and multivariate analyses of DFS

From: Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy

Variables

Disease-free survival

Univariate analyses

p

Multivariate analyses

p

Hazara ratios

Hazara ratios

(95%CI)

(95%CI)

Sex

0.938(0.556–1.583)

0.811

  

Age

1.003(0.980–1.027)

0.804

  

BMI

0.986(0.917–1.060)

0.698

  

Smoke

1.007(0.605–1.676)

0.978

  

pT stage

    

 pT2

Ref.

   

 pT3

2.017(1.156–3.520)

0.014

1.683(0.906–2.810)

0.155

 pT4

6.303(3.066–12.956)

< 0.001

7.536(3.131–11.235)

< 0.001

NLR

0.365(0.213–0.625)

< 0.001

0.282(0.138–0.575)

< 0.001

PLR

1.030(0.624–1.700)

0.908

  

MLR

0.607(0.371–0.995)

0.049

1.152(0.604–2.196)

0.668

Chemotherapy

1.597(0.835–3.056)

0.157

  

Adverse events

0.541(0.315–0.929)

0.026

0.444(0.254–0.776)

0.004

  1. CI Confidence interval, NLR Neutrophil-to-lymphocyte ratio, PLR Platelet-to-lymphocyte ratio, MLR Monocyte-to-lymphocyte ratio, irAEs Immune-related adverse events